New cystic fibrosis treatment drug approved by the FDA
I remember growing up with my sister and watching her take handfuls of enzymes with every meal for cystic fibrosis. She also did numerous breathing treatments every day. Whether it was her nebulizers or other breathing exercises, I remember understanding that “treatments” were going to be a large part of her day-to-day life.
In a press release from Cystic Fibrosis Today, JBK heard the wonderful news last week that Vertex Pharmaceuticals received FDA approval on their new drug Trikafta (elexacafor, tezacaftor and ivacaftor). JBK Search and our family is ecstatic for what this will do for Katelin Patterson and the thousands of people affected by this disease. This triple combination treats people with the most common CF-causing mutation that is found in almost 90% of all CF patients. This means that a huge number of patients will have the opportunity to benefit from Trikafta.
This triple-combination drug will be so useful to the CF community that the FDA expedited the approval process. We love that this drug got marked for accelerated approval because we believe this drug will save many lives!
Each year we push ourselves further and further to reach a cure for cystic fibrosis. This news in medicine has given a new boost of focus for JBK Search to finish out the rest of the year stronger than ever and set our sights even higher for the New Year.
For more information read the full press release here!